Ambrx Biopharma Inc. (AMAM) stock rallied over 0.42% intraday to trade at $2.38 a share on NYSE. The stock opened with a gain of 1.28% at $2.35 and touched an intraday high of $2.48, rising 0.42% against the last close of $2.37. The stock went to a low of $2.38 during the session.
Number of Shares
Cash Flow per Share
Free Float in %
Sales or Revenue7.46 Million
5Y Sales Change-
Fiscal Year Ends2021-12-30
Ambrx Biopharma Inc., a clinical-stage biologics company, discovers and develops engineered precision biologics using its proprietary expanded genetic code technology platform. Its lead product candidate is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is investigated in various clinical trials for the treatment of breast cancer, gastric/gastroesophageal junction cancer, and other solid tumors, including ongoing Phase 2/3 clinical trials for the treatment of HER2-positive metastatic breast cancer and gastric cancer. The company is also developing two earlier-stage product candidates, including ARX517, an anti-PSMA ADC, which is in a Phase 1 clinical trial for the treatment of prostate cancer and other solid tumors; and ARX305, an anti-CD70 ADC in investigational new drug-enabling studies for the treatment of renal cell carcinoma and other cancers. In addition, it is developing other multiple product candidates targeting immuno-oncology applications, which include ARX822, a fab-small molecule bispecific that is in preclinical development for cancers; and ARX102, an immuno-oncology IL-2 pathway agonist to stimulate the patient's own immune system by targeting the ß and gamma receptors on the cytotoxic T cell. Ambrx Biopharma Inc. has collaborations with Bristol Myers Squibb Company; AbbVie Inc.; BeiGene; Sino Biopharmaceutical Co., Ltd.; NovoCodex; and Elanco Animal Health. The company was incorporated in 2003 and is headquartered in La Jolla, California.
Ambrx Biopharma Inc. (NYSE: AMAM) stock price is $2.38 as of the last check on Monday, August 8. During the trading session, AMAM stock reached the peak price of $2.48 while $2.38 was the lowest point it dropped to.
The NYSE listed AMAM is part of Biotechnology industry that operates in the broader Health Care sector. Ambrx Biopharma Inc. , a clinical-stage biologics company, discovers and develops engineered precision biologics using its proprietary expanded genetic code technology platform.
Dr. Feng Tian Ph.D.
Pres, Member of Scientific Advisory Board, CEO & Chairman
Ms. Sonja Nelson CPA
Chief Financial Officer
Dr. Shawn Shao-Hui Zhang Ph.D.
Exec. VP of R&D Operations and GM of Ambrx China
Dr. Janice Lu M.D., Ph.D.
Chief Medical Officer
AMAM stock traded closed the last session at $2.38, which is $0.009999999999999787 or 0.42194092827003316% lower than its previous close of $2.37. AMAM's current trading price is 2.15% lower than its 52-week high of $19.5 where as its distance from 52-week low of 2.33% is -87.79%.
Number of AMAM employees currently stands at -. AMAM operates from 10975 North Torrey Pines Road, La Jolla, CA 92037, United States.
Official Webiste of $AMAM is: https://ambrx.com
AMAM stock volume for the day was 13,837 shares while in the previous session number of AMAM shares traded was 13,837 . The average number of AMAM shares traded daily for last 3 months was 9.88 Thousands.
The percentage change in AMAM stock occurred in the recent session was 0.42194092827003316% while the dollar amount for the price change in AMAM stock was $0.009999999999999787.
In the recent session, the day high for AMAM stock was $2.48 while the low for AMAM stock touched on the day was $2.38.
The market value of AMAM currently stands at 91.08 Million with its latest stock price at $2.38 and 42.22 Million of its shares outstanding.